↓ Skip to main content

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Overview of attention for article published in Breast Cancer Research, December 2019
Altmetric Badge

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
8 Mendeley